TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04868617

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATTRACT-I
Description: The aim of this investigation is to evaluate the performance and safety of an ostomy baseplate with a novel skin protection technology and its ability to reduce peristomal skin complications compared to SenSura® Mio. The subject will be randomized to either test product or comparator at enrollment. The subject will wear the test product for approximately 35 days and then cross-over to the comparator (or vice-versa) for approximately 35 days. At each baseplate change, the subject will answer questions about their skin, and take pictures of their stoma and used baseplate. They will also answer quality of life questionnaires at each study visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATTRACT-I
Description: The aim of this investigation is to evaluate the performance and safety of an ostomy baseplate with a novel skin protection technology and its ability to reduce peristomal skin complications compared to SenSura® Mio. The subject will be randomized to either test product or comparator at enrollment. The subject will wear the test product for approximately 35 days and then cross-over to the comparator (or vice-versa) for approximately 35 days. At each baseplate change, the subject will answer questions about their skin, and take pictures of their stoma and used baseplate. They will also answer quality of life questionnaires at each study visit.
Study: NCT06524687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imvotamab
Description: Administered intravenously
Study: NCT06185517

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Questionnaire translation and validation
Description: Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ). Validation of a French translation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Questionnaire translation and validation
Description: Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ). Validation of a French translation
Study: NCT05792813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGYY
Description: LGYY = Linggui Yangyuan paste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LGYY mimetic
Description: LGYY = Linggui Yangyuan paste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WZYZ
Description: WZYZ= Wuzi Yanzong oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WZYZ mimetic
Description: WZYZ= Wuzi Yanzong oral solution
Study: NCT04985721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 40 mg orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg IV every 21 days
Study: NCT05356832

Intervention type: DIAGNOSTIC_TEST
Intervention: Pelvic Floor Health Knowledge Quiz
Description: It is a questionnaire to measure the knowledge level of the participants about pelvic floor health.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pelvic Floor Health Knowledge Quiz
Description: It is a questionnaire to measure the knowledge level of the participants about pelvic floor health.
Study: NCT06009367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation by Stecco method
Description: Fascial Manipulation (FM) is a method carefully developed by members of the Stecco family after many years of research. FM involves deep kneading of the muscle fascia at specific points called centers of coordination (CC) and centers of fusion (CF) along myofascial sequences, diagonals, and spirals. It has been proposed that the friction caused by manipulation creates localized heat and that, due to the thermosensitive characteristics of fascia, this heat facilitates the transition of hyaluronic acid within the extracellular matrix from a condensed state to a more fluid state, thus restoring the gliding properties of fascia.
Study: NCT04537494

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri
Description: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: L. reuteri
Description: Probiotic
Study: NCT05599932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siremadlin
Description: HDM201 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siremadlin
Description: HDM201 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siremadlin
Description: HDM201 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siremadlin
Description: HDM201 capsule
Study: NCT05517187

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: Regenerative endodontic treatment induced with blood clot in root canal space as a secondary treatment for failed root canal treated incisors

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: Regenerative endodontic treatment with platelet rich fibrin in root canal space as a secondary treatment for failed root canal treated incisors
Study: NCT06239597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: occupation-based lifestyle intervention
Description: 9 week lifestyle course

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other courses
Description: Other courses in the same university, during the same academic years.
Study: NCT06396364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Treatment group: the ankle was immobilized in a walking boot, then a third-generation cryotherapy device (Z- One®, Zamar) was applied daily for 2 hours two times a day up to the day of surgery. The walking boot was removed when the cryotherapy device was applied.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Treatment group: the ankle was immobilized in a walking boot, then a third-generation cryotherapy device (Z- One®, Zamar) was applied daily for 2 hours two times a day up to the day of surgery. The walking boot was removed when the cryotherapy device was applied.
Study: NCT05737368

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fractionated radiotherapy
Description: fractionated radiotherapy (500cGy \*5F, 600cGy\*5F, 350cGy\*10F, according to the tumor volume)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab
Description: Cardunizumab (10mg/kg, Q3W, d1)
Study: NCT05087901

Intervention type: DIAGNOSTIC_TEST
Intervention: Multifocal electroretinogram
Description: A device that records electric potentials generated by the retinal photoreceptors and neural elements in a multifocal fashion
Study: NCT04186364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned Ambassador
Description: If assigned to the intervention group, participants will be assigned a medical student ambassador on arrival to the Emergency Department. A brief discussion may take place to review the child's history and survey results, and a copy of the survey will be placed near the patient's bedside for healthcare personnel to review. The student ambassador will accompany the child and their family through key points of their visit and will be expected to make accommodations for the child as determined by the accommodation survey results. The family will be required to allow the ambassador to stay throughout the ED visit.
Study: NCT05525689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntelliCare
Description: Application with patient-facing tools for depression symptom monitoring, self-management, and care manager communication as well as care manager dashboards for workflow optimization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COMPASS-Care
Description: Website with content specific to perinatal depression and standard EHR-based tools for patient communication
Study: NCT04836689

Intervention type: DEVICE
Group type: OTHER
Intervention: nasal intermittent positive pressure ventilation (NIPPV).
Description: NIPPV will be administered using Leoni (Heinen\&Löwenstein, Bad Ems, Germany) and RAM cannula (Neotech, Valencia, CA).~After initial setting and before routine blood gas testing, tcCO2 will be connected and calibrated. We will use SenTec digital monitor (SenTec AG, Therwil, Switzerland). Correlation/agreement between the tcCO2 and PCO2 will be assessed and documented in each infant.~For Each infant we will get 2 set of data: Change in measurements when changing from 30 bpm to 10 bpm, and change in measurements when changing from 10 bpm to 30 bpm At the end of each hour, before rate change, we will document the following measurements:TcCO2, FiO2, saturation, the infant's respiratory rate (as measured in the monitor), number of apneas, bradycardia (heart rate\<100 bpm), saturation\<90% and\>94% episodes (as measured in the monitor), 1-hour saturation histogram clasification.

Intervention type: DEVICE
Group type: OTHER
Intervention: nasal intermittent positive pressure ventilation (NIPPV).
Description: NIPPV will be administered using Leoni (Heinen\&Löwenstein, Bad Ems, Germany) and RAM cannula (Neotech, Valencia, CA).~After initial setting and before routine blood gas testing, tcCO2 will be connected and calibrated. We will use SenTec digital monitor (SenTec AG, Therwil, Switzerland). Correlation/agreement between the tcCO2 and PCO2 will be assessed and documented in each infant.~For Each infant we will get 2 set of data: Change in measurements when changing from 30 bpm to 10 bpm, and change in measurements when changing from 10 bpm to 30 bpm At the end of each hour, before rate change, we will document the following measurements:TcCO2, FiO2, saturation, the infant's respiratory rate (as measured in the monitor), number of apneas, bradycardia (heart rate\<100 bpm), saturation\<90% and\>94% episodes (as measured in the monitor), 1-hour saturation histogram clasification.
Study: NCT04700332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCFPyL PET/CT
Description: Prostate Membrane Specific Antigen-specific imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCFPyL PET/CT
Description: Prostate Membrane Specific Antigen-specific imaging
Study: NCT04835077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Structured aerobic exercises (Each session will consist of 50 minutes and will be divided into three parts: 5 minutes of warm-up exercises, 40 minutes of aerobic exercises, 5 minutes of cool down exercises) will be taught in the first session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postural stabilization exercises
Description: Structured postural stabilization exercises (strengthening exercises, balance-coordination exercises, flexibility exercises) will be taught in the first session.
Study: NCT06431477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan
Description: QD, PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: QD, PO
Study: NCT05317845

Intervention type: OTHER
Intervention: No treatment given
Description: The clinical management and prescribed treatment of diabetes and eASCVD/ASCVD risk factors are independent of this study and are part of the routine clinical practice at the discretion of the treating physician.
Study: NCT06275139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Assessment of Cervicocerebral Vessels
Description: Integrated assessment of cervicocerebral vessels shall be performed, including transcranial color-coded doppler, cerebral perfusion with multislice CT, and cognitive function assessment.
Study: NCT06077253

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Iridotomy
Description: Peripheral iridotomy (size \>200µm)
Study: NCT05606731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Childhood Obesity Intervention
Description: The study will focus on the effectiveness of a community- and family-based intervention that will involve multiple family caregivers. The intervention will include in-person and mobile phone components focusing on Latino caregivers of young children, to support evidence-based and age appropriate dietary, media-viewing, and physical activity practices among 2- to 5-year old children.
Study: NCT05289115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group/ Active HD-tDCS
Description: Patients enrolled in this group will received 20 minutes of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) during 10 sessions. It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Group / Sham Group
Description: 10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
Study: NCT05417737

Intervention type: OTHER
Intervention: Ozone therapy
Description: Systemic and/or local ozone administration. Dosage, frequency, and duration of ozone treatment will depend on the treated symptom and clinical evolution. Usually planned 40 sessions.
Study: NCT05010096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib
Description: Given PO
Study: NCT04864249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNOO
Description: The SNOO is a commercially available device which is a responsive bassinet for neonates. The bassinet is designed to respond to the infant's cries and automatically respond by emitting engineered white noise sounds and providing a rhythmic rocking motion. The infant is also swaddled to remain securely back-down. The SNOO automatically increases the emitted sound and motion if the infant is still crying. However, if the infant does not settle within 3 minutes, the SNOO will shut off and alert the adults for additional assistance. Parents can also modify the SNOO settings to meet the baby's need for sound and/or motion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safe sleep education in the postpartum period
Description: Comprised of education from the postpartum clinical nurse with a corresponding educational handout to take home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Safe sleep education in the postpartum period
Description: Comprised of education from the postpartum clinical nurse with a corresponding educational handout to take home
Study: NCT06002217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Patients in the tap block arm will receive an injection of levobupivacaine 2.5mg/ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tap block
Description: Patients in the placebo arm will receive an injection of salin solution 2.5mg/ml , in the same way as tap block
Study: NCT05653570

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Electrical stimulation will be used to confirm needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound guidance will be used to visualize needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guidance will be used to visualize needle and catheter placement within the interfascial plane between the erector spinae muscle and thoracic transverse process.
Study: NCT06086821

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Re-Evaluation
Description: Recording of the periodontal charting

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Periodontal Re-Evaluation
Description: Recording of the periodontal charting
Study: NCT05694039

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aids
Description: The intervention group uses hearing aids, and the intervention group receives hearing aid intervention for 5 years.
Study: NCT05255887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informing Patients With Video
Description: 24-48 hours before the surgery, the patients will be shown an informative video about the intensive care environment in a separate room through a one-on-one interview. (The content of the training to be done with the video is stated in the appendix) In the study, no attempt will be made to the control group patients other than the routine practice of the institution before the surgery. In the study, the day of discharge from the intensive care unit will be counted as the first day, and on the second day, the 'Intensive Care Experience Scale' will be applied to the patients in both the experimental and control groups by face-to-face interview method.
Study: NCT05712070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-guided lifestyle modification
Description: Smart watch and smartphone application-based life style modification for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A book-based self-education of lifestyle modification
Description: A take-home book-based self-education for lifestyle modification
Study: NCT04872192

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transversus thoracic muscle plane block
Description: transversus thoracic muscle plane block by injection of 15 ml of bupivacaine 0.25% on each side combined with general anaesthesia

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: general anaesthesia
Description: transversus thoracic muscle plane block by injection of 15 ml of saline on each side combined with general anaesthesia
Study: NCT05064371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Concentrate for solution for IV infusion
Study: NCT05125484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental Bowen Technique
Description: Patient was in lying position. Therapist placed thumb on the effected side muscke. Then hooked thumb on lateral edge of muscle to apply pressure against the muscle. Took a pause. Thumb flattened in a medial direction and pluck was created in muscle.~Set of 15-20 bowen moves on upper , middle and lower fibres each with 2 mins gap between each set.~Total treatment time: 20 mins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Myofacial release technique
Description: Patient was in lying position. MFR applied via ulnar border of both palms while patient being in contralateral side flexion.~20 mins
Study: NCT05373446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 300mg
Description: SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSD8432 750mg
Description: SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSD8432Placebo
Description: SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID
Study: NCT06012253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Based Walking Program
Description: The intervention group will be applied to Home Based Walking Program. It was aimed that the patients should do at least 150 minutes of moderate-intensity physical exercise per week for up to 8 weeks. The content of the program includes a walking information booklet (information notes, activity chart and obstacle avoidance form), exercise diary, face-to-face-telephone counseling, sending text messages, prepared in line with international guides. It was planned to give weekly counseling to the patients included in the intervention group for an 8-week period.
Study: NCT05011227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 2 cycles Camrelizumab before endoscopic surgery and one year after

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic surgery
Description: standard endoscopic surgery for recurrent nasopharyngeal carcinoma
Study: NCT06355427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-FAPI PET-CT
Description: \[18F\]F-FAPI PET-CT in addition to regular CT and MRI, prior to participants undergoing surgery
Study: NCT06008327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical 15% Trichloroacetic acid
Description: Recently trichloroacetic acid (TCA), a superficial chemical exfoliative agent has shown efficacy in treating acanthosis nigricans. Data from this would help in establishing it as a treatment of choice thereby lead to reduction in cost and benefit the patient both financially and psychologically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical 15% Trichloroacetic acid
Description: Recently trichloroacetic acid (TCA), a superficial chemical exfoliative agent has shown efficacy in treating acanthosis nigricans. Data from this would help in establishing it as a treatment of choice thereby lead to reduction in cost and benefit the patient both financially and psychologically.
Study: NCT05120726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dehydrated human amnion/chorion membrane
Description: Dehydrated human amnion/chorion membrane (dHACM) has been commercially available for nearly 15 years. dHACM has been shown to elute growth factors including platelet-derived growth factors, fibroblast growth factors (PDGF), fibroblast growth factors (FGF), transforming growth factor beta 1 (TGF-β1), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and placental growth factor (PlGF). Additionally, dHACM exerts immunomodulatory effects by releasing anti-inflammatory interleukins and factors which help regulate the matrix metalloproteinase (MMP) activity. Furthermore, dHACM has also been shown to stimulate mesenchymal stem cell migration and recruitment. dHACM is routinely utilized in the management of chronic wounds including diabetic ulcer and venous ulcers.
Study: NCT05980481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.5 mg/kg intravenous infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.5 mg/kg intravenous infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.5 mg/kg intravenous infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Injection
Description: First load dose is 8.0mg , then 6.0 mg/kg intravenous infusion every 3 weeks